RxDoctor Payments Data

Walter Little, MD

Urology · Gallatin, TNNPI 1760460208

Payments from drug & device makers

$9,247in general payments, 2019–2025

Across 463 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$2K
  • Sumitomo Pharma America, Inc.$785
  • Johnson & Johnson$760
  • Dendreon Pharmaceuticals LLC$640
  • Pfizer$602
  • Myriad Genetic Laboratories, Inc.$554
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$9,03598%
  • Education$2002%
  • Entertainment$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,247 in reported general payments places this provider in the 70th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$194,580
Medicare patients
638
Services billed
4,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix61$152,278
MyrbetriqMirabegron107$81,235
GemtesaVibegron40$23,369
PremarinEstrogens, Conjugated34$14,476
Tamsulosin Hcl851$13,900
Finasteride549$7,733
Potassium Citrate ErPotassium Citrate57$5,978
Oxybutynin Chloride ErOxybutynin Chloride171$3,547
Estradiol49$2,668
Testosterone Cypionate28$1,707
Alfuzosin Hcl ErAlfuzosin Hcl66$1,656
NitrofurantoinNitrofurantoin Macrocrystal27$1,361
Desmopressin Acetate24$1,241
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim76$579
Cephalexin65$564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$785$175,647101 claims
Astellas Pharma US IncMyrbetriq$1,993$81,235107 claims
PfizerPremarin$602$14,47634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 276 urology providers in Tennessee.

Other urology in Gallatin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →